Surge announces closing of a €7.5 million fundraising round to decrypt the immune system and transform precision medicine
Surge, specialized in high-dimensional immune system analysis combined with artificial intelligence, is paving the way for a new era of precision medicine. With the launch of PreCyte®, its flagship product predicting post-operative complications, and the inauguration of SurgeLab™, a premier laboratory dedicated to the discovery of immune biomarkers, Surge aims to transform healthcare pathways, optimize patient care, and reduce hospitalization stays.
PARIS, March 27, 2024 — Surge has just closed its second round of funding, raising €7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov’, as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé. The fundraising is complemented by grants from BPI, including support for deep tech development and the Future Investment Program, of which Surge was a laureate.
This second round of funding, marked by the entry of strategic investors, reflects Surge’s accelerated development and the beginning of the commercial expansion phase. This funding will enable the opening of SurgeLab™, a premier laboratory dedicated to the discovery of immune biomarkers, and the finalization of PreCyte®‘s industrialization. It will also support the refinement of its cutting-edge AI algorithms. “Building on solid scientific and technical fundamentals, Surge has already demonstrated the relevance of its biomarker discovery platform to address concrete clinical needs and integrate precision medicine into surgical care. Impressed by the team’s speed and accuracy of execution, we are delighted to support Surge whose challenge in the coming months is to make PreCyte® solution available to as many people as possible, and to generalize the tech approach to new clinical use cases. An exciting double challenge between contribution to academic research and innovation in care pathways!” Maxime Huerre, Vice President – Venture at Eurazeo
Promising clinical results, paving the way for precision medicine in complex surgery
The launch of PreCyte® marks a major milestone in Surge’s long-term strategy, which aims to develop a comprehensive ecosystem of tools for precision medicine. This initiative is a decisive step towards personalized care for surgical patients.
Through partnerships with several renowned institutions including Foch Hospital and AP-HP, Surge has completed its first large-scale clinical trial validating PreCyte®, its predictive test for postoperative complications, with 283 patients undergoing major surgeries. PreCyte®‘s initial results demonstrate predictive capacity up to three times higher than existing solutions. “Validating our product in partnership with internationally renowned institutions represents a crucial step in the mission we have set for ourselves. With PreCyte, the objective is not only to predict postoperative complications but also to pave the way for the precision medicine of tomorrow. By revolutionizing the predictive approach in surgery through immune system analysis, we can envision a real transformation of healthcare pathways to significantly reduce surgery-associated risks. Moreover, this study provided an opportunity to present our innovative approach to other medical or interventional specialties, thus opening up new development prospects for the future.” Julien Hédou, co-founder & CEO of Surge.
The artificial intelligence algorithm, Stabl, redefines the discovery of predictive biomarkers
Building on its clinical advances, Surge’s AI technology has also made substantial progress. The publication of an article in Nature Biotechnology in January 2024 highlights the capabilities of its patented algorithm called Stabl. This revolutionary algorithm identifies a sparse and reliable set of biomarkers, effectively translating high-dimensional data into clinically relevant signatures, enabling true personalized medicine. “Stabl represents a significant advancement in the use of AI for biomarker discovery. Before Stabl’s arrival, identifying reliable predictive signatures with fewer than 20 biomarkers was a daunting, if not impossible, task. Stabl changes the game, offering a robust and effective solution that will benefit both academic institutions and players in the biotechnology and pharmaceutical sectors. This innovation is the result of years of research and represents a major advance in our quest to understand and leverage biomarkers.” Brice Gaudillière, co-founder of Surge and Associate Professor at Stanford University, USA.
Surge inaugurates SurgeLab™, a center of excellence for high-dimensional immune analysis
This fundraising marks a turning point in Surge’s development, notably with the launch of SurgeLab™, an analytic laboratory specialized in decrypting the immune system. This unique platform provides a high-resolution map of the immune system, with several thousand parameters analyzed per blood sample. Surge is already deploying the analysis capacity of its platform with several research institutions to offer unprecedented information density results. “The launch of SurgeLab™ is a major advancement in our ability to understand the immune system. As a partner, this cutting-edge technology allows us to explore human biology in an unprecedented way, offering unmatched precision and depth of analysis. This is made possible by Surge’s unique approach to AI.” Ina Stelzer, Assistant Professor at the University of California, San Diego.
For more information, please contact:
Natacha Heurtault/nh@early-com.com/+06 12 23 58 60
About Surge:
Founded with the goal of revolutionizing precision medicine, Surge is an innovative company specializing in in-depth understanding of the immune system using AI. Thanks to significant technological advancements and a team of top-notch researchers, Surge is committed to creating innovative solutions to pave the way for personalized medicine of tomorrow. With the launch of its first product, PreCyte®, for predicting the risk of postoperative complications, and its premier laboratory, SurgeLab™, for acquiring individualized immune signatures, the company aims to become a leader in precision immune analysis. https://www.surge.care/
About Eurazeo:
Eurazeo is a leading European investment group managing €35.0 billion of diversified assets, of which €24 billion are invested on behalf of third parties in a portfolio of nearly 600 companies. With expertise in Private Equity, private debt, real estate, and infrastructure assets, the Group supports companies of all sizes, leveraging the commitment of its over 400 employees, its deep sectoral expertise, privileged access to global markets, and its responsible approach to value creation based on growth. Its institutional and family shareholders, its strong financial structure without structural debt, and its flexible investment horizon allow it to partner with companies over the long term. Eurazeo has offices in Paris, New York, London, Frankfurt, Berlin, Milan, Madrid, Luxembourg, Shanghai, Seoul, Singapore, and Sao Paulo. Eurazeo is listed on Euronext Paris. ISIN: FR0-001
